Wayne Kuznar
Wayne Kuznar is a contributor to Urology Times.
Novel VEGF inhibitor may play role in advanced renal cell carcinoma
Use of tivozanib, an experimental tyrosine kinase inhibitor (TKI) with increased specificity and potency for the vascular endothelial growth factor (VEGF) receptor, as initial targeted therapy for patients with advanced renal cell carcinoma did not translate into improved overall survival compared with sorafenib (Nexavar) in a phase III clinical trial.
Post-radical prostatectomy outcomes not influenced by advanced age
Advanced age does not influence postoperative continence or cancer-specific survival after radical prostatectomy, according to a recent study.
Zero-ischemia nephrectomy appears safe, efficacious
A technique of zero-ischemia robotic partial nephrectomy (RPN) using near-infrared fluorescence imaging appears to be associated with better postoperative kidney function compared with conventional RPN with main-artery renal clamping.
Expulsive therapy less costly than surgery for renal colic
Medical expulsive therapy for the initial management of uncomplicated acute renal colic, with eventual uretereoscopy if needed, is associated with less resource utilization and lower 6-week costs than early surgery, say researchers from the University of Michigan, Ann Arbor.
Ureteral sheath may induce severe ureteric injuries
Insertion of a ureteral access sheath during retrograde intra-renal surgery may induce severe ureteric injuries, according to a prospective analysis of 136 patients undergoing procedures using ureteral access sheaths.
Bladder cancer remission improved by adding electromotive mitomycin to BCG
In patients with stage pT1 urothelial bladder cancer, intravesical bacillus Calmette-Guérin (TheraCys, TICE BCG) combined with electromotive mitomycin-C produces higher remission rates and longer remission times than BCG alone, Italian researchers reported.
Study questions botulinum’s efficacy in post-BPH overactive bladder
Intradetrusor injections of onabotulinumtoxinA (Botox) do not significantly reduce urinary frequency in patients with refractory overactive bladder secondary to BPH, results from a two-institution, placebo-controlled study indicate.
180W BPH laser reduces operative time, fiber usage
Photoselective vaporization of the prostate using the GreenLight XPS 180W laser system (American Medical Systems, Minnetonka, MN) is associated with reduced operative time and fiber usage compared with the GreenLight HPS 120W while resulting in lower PSA levels 6 months post-procedure.
Holmium laser enucleation of the prostate safe in patients with large prostates, study indicates
In experienced hands, holmium laser enucleation of the prostate in men with BPH with glands 200 grams or greater yields outcomes similar to those of simple open prostatectomy with much less morbidity, according to a retrospective review at a single center.
Antibiotics not beneficial in men with elevated PSA
Empiric use of antibiotics for a newly elevated PSA measurement in asymptomatic men appears to have no clinical benefit, according to results of a recent multicenter study.